SCHEMBL31579019

SCHEMBL31579019

O=S(=O)(Cl)c1cn(-c2ccccc2)nn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.51
NOTUM Q6P988 2/20 0.46
MAOA P21397 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CA1 P00915 8/20 0.46
CA2 P00918 8/20 0.46
CA9 Q16790 7/20 0.46
CA12 O43570 6/20 0.46
PTGS2 P35354 2/20 0.44
CA5A P35218 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
PTGS1 P23219 1/20 0.44
ALDH1A1 P00352 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ESRRA P11474 1/20 0.41
CA4 P22748 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
DRD2 P14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18007612 0.73 KDM1A (0.46) L3MBTL1ALDH1A1HSD17B10TDP1
SCHEMBL25233234 0.69 GRM4 (0.48) PTGS2ALDH1A1HSD17B10TDP1DRD2
SCHEMBL2819653 0.68 P2RX7 (1.00) P2RX7NOTUMMAOAL3MBTL1CA1
SCHEMBL23153549 0.68 ESRRA (0.59) P2RX7NOTUMMAOAL3MBTL1CA1
SCHEMBL14605595 0.68 ALDH1A1 (0.52) ALDH1A1HSD17B10TDP1DRD2DRD4
SCHEMBL6030190 0.67 NOTUM (0.58) P2RX7NOTUMMAOAL3MBTL1CA1
SCHEMBL12959177 0.67 P2RX7 (0.55) P2RX7NOTUMMAOAL3MBTL1CA1
SCHEMBL23028378 0.67 NOTUM (0.58) P2RX7NOTUMMAOAL3MBTL1ESRRA
SCHEMBL17039112 0.67 P2RX7 (0.55) P2RX7NOTUMMAOAL3MBTL1CA1
SCHEMBL2629357 0.67 P2RX7 (0.55) P2RX7NOTUMMAOAL3MBTL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161281-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161281-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBPL, EBP, CREBBP P2RX7 4826/4885NOTUM 1891/4885MAOA 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.